Evidence map›Paper›PMID 32930516›Full record

ArticlePharmacology research & perspectives2020

A novel approach to nonsurgical sterilization; application of menadione-modified gonocyte-targeting M13 bacteriophage for germ cell ablation in utero.

Barbara A Fraser, Kasey Miller, Natalie A Trigg, Nathan D Smith, Patrick S Western, Brett Nixon, Robert J Aitken

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Barbara A FraserPriority Research Centre for Reproductive Science, The University of Newcastle, Callaghan, NSW, Australia.
Kasey MillerPriority Research Centre for Reproductive Science, The University of Newcastle, Callaghan, NSW, Australia.
Natalie A TriggPriority Research Centre for Reproductive Science, The University of Newcastle, Callaghan, NSW, Australia.
Nathan D SmithAnalytical and Biomolecular Research Facility, The University of Newcastle, Callaghan, NSW, Australia.
Patrick S WesternCentre for Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Brett NixonPriority Research Centre for Reproductive Science, The University of Newcastle, Callaghan, NSW, Australia.
Robert J AitkenPriority Research Centre for Reproductive Science, The University of Newcastle, Callaghan, NSW, Australia.ORCID 0000-0002-9152-156X
Hunter Medical Research Institute · AUHudson Institute of Medical Research · AUUniversity of Newcastle Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There remains a compelling need for the development of nonsurgical sterilizing agents to expand the fertility management options for both domestic and feral animal species. We hypothesize that an efficacious sterilization approach would be to selectively ablate nonrenewable cell types that are essential for reproduction, such as the undifferentiated gonocytes within the embryonic gonad. Here, we report a novel strategy to achieve this goal centered on the use of a chemically modified M13 bacteriophage to effect the targeted delivery of menadione, a redox-cycling naphthoquinone, to mouse gonocytes. Panning of the M13 random peptide 'phage display library proved effective in the isolation of gonocyte-specific targeting clones. One such clone was modified via N-succinimidyl-S-acetylthioacetate (SATA) linkage to the N-terminus of the major PVIII capsid protein. Subsequent deacetylation of the SATA was undertaken to expose a thiol group capable of reacting with menadione through Michael addition. This chemical modification was confirmed using UV spectrophotometry. In proof-of-concept experiments we applied the modified 'phage to primary cultures of fetal germ cells and induced, an approximately, 60% reduction in the viability of the target cell population. These studies pave the way for in vivo application of chemically modified M13 bacteriophage in order to achieve the selective ablation of nonrenewable cell types in the reproductive system, thereby providing a novel nonsurgical approach the regulation of fertility in target species.

Indexed as

AnimalsBacteriophage M13Capsid ProteinsCell SurvivalFemaleGerm CellsMaleMiceOvaryPeptide LibraryProof of Concept StudySterilization, ReproductiveSuccinimidesSulfidesTestisVitamin K 3Capsid ProteinsN-hydroxysuccinimide S-acetylthioacetatePeptide LibrarySuccinimidesSulfidesVitamin K 3bacteriophagecontraceptivegonocytesmenadione(MeSH): 'phage displayROS

Identifiers

PMID32930516
PMCPMC7507010
OpenAlexW3086664918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.